Variable CD52 expression in mature T cell and NK cell malignancies

Implications for alemtuzumab therapy

Liuyan Jiang, Constance M. Yuan, Julia Hubacheck, John Edward Janik, Wyndham Wilson, John C. Morris, Gregory A. Jasper, Maryalice Stetler-Stevenson

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92·3%), ATLL (94·1%) and CTCL (87·5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.

Original languageEnglish (US)
Pages (from-to)173-179
Number of pages7
JournalBritish Journal of Haematology
Volume145
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

T-Cell Lymphoma
Natural Killer Cells
Natural Killer T-Cells
T-Lymphocytes
Prolymphocytic Leukemia
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Adult T Cell Leukemia Lymphoma
Neoplasms
Flow Cytometry
Therapeutics
Anti-Idiotypic Antibodies
Lymphoma
alemtuzumab

Keywords

  • Alemtuzumab
  • CD52
  • Flow cytometry
  • NK cell lymphoma
  • T cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Jiang, L., Yuan, C. M., Hubacheck, J., Janik, J. E., Wilson, W., Morris, J. C., ... Stetler-Stevenson, M. (2009). Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab therapy. British Journal of Haematology, 145(2), 173-179. https://doi.org/10.1111/j.1365-2141.2009.07606.x

Variable CD52 expression in mature T cell and NK cell malignancies : Implications for alemtuzumab therapy. / Jiang, Liuyan; Yuan, Constance M.; Hubacheck, Julia; Janik, John Edward; Wilson, Wyndham; Morris, John C.; Jasper, Gregory A.; Stetler-Stevenson, Maryalice.

In: British Journal of Haematology, Vol. 145, No. 2, 01.04.2009, p. 173-179.

Research output: Contribution to journalArticle

Jiang, L, Yuan, CM, Hubacheck, J, Janik, JE, Wilson, W, Morris, JC, Jasper, GA & Stetler-Stevenson, M 2009, 'Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab therapy', British Journal of Haematology, vol. 145, no. 2, pp. 173-179. https://doi.org/10.1111/j.1365-2141.2009.07606.x
Jiang, Liuyan ; Yuan, Constance M. ; Hubacheck, Julia ; Janik, John Edward ; Wilson, Wyndham ; Morris, John C. ; Jasper, Gregory A. ; Stetler-Stevenson, Maryalice. / Variable CD52 expression in mature T cell and NK cell malignancies : Implications for alemtuzumab therapy. In: British Journal of Haematology. 2009 ; Vol. 145, No. 2. pp. 173-179.
@article{e84f2ca9308e4d23a63ddf70c7c2155d,
title = "Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab therapy",
abstract = "The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92·3{\%}), ATLL (94·1{\%}) and CTCL (87·5{\%}), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50{\%}) and ENT/NKCL (25{\%}). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.",
keywords = "Alemtuzumab, CD52, Flow cytometry, NK cell lymphoma, T cell lymphoma",
author = "Liuyan Jiang and Yuan, {Constance M.} and Julia Hubacheck and Janik, {John Edward} and Wyndham Wilson and Morris, {John C.} and Jasper, {Gregory A.} and Maryalice Stetler-Stevenson",
year = "2009",
month = "4",
day = "1",
doi = "10.1111/j.1365-2141.2009.07606.x",
language = "English (US)",
volume = "145",
pages = "173--179",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Variable CD52 expression in mature T cell and NK cell malignancies

T2 - Implications for alemtuzumab therapy

AU - Jiang, Liuyan

AU - Yuan, Constance M.

AU - Hubacheck, Julia

AU - Janik, John Edward

AU - Wilson, Wyndham

AU - Morris, John C.

AU - Jasper, Gregory A.

AU - Stetler-Stevenson, Maryalice

PY - 2009/4/1

Y1 - 2009/4/1

N2 - The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92·3%), ATLL (94·1%) and CTCL (87·5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.

AB - The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92·3%), ATLL (94·1%) and CTCL (87·5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.

KW - Alemtuzumab

KW - CD52

KW - Flow cytometry

KW - NK cell lymphoma

KW - T cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=63149129736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63149129736&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07606.x

DO - 10.1111/j.1365-2141.2009.07606.x

M3 - Article

VL - 145

SP - 173

EP - 179

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -